Drugs / MenSCs
MenSCs
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01496339 | Jan 2012 → Dec 2013 | type 1 diabetes mellitus | S-Evans Biosciences Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01483248 | Oct 2010 → Oct 2013 | cirrhosis of liver | S-Evans Biosciences Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenSCs | “MenSCs transplantation: taken i.v., twice per week, at a dose of 1\*10E6 MSC/kg body for 2 weeks.” NCT01483248 ↗ |
| Known as | human menstrual blood-derived mesenchymal stem cells | “The purpose of this study is to investigate whether the treatment of human menstrual blood-derived mesenchymal stem cells which would be applied to diabetes patients is safe...” NCT01496339 ↗ |
| Known as | Menstrual blood-derived stem cells(MenSCs) | “Menstrual blood-derived stem cells(MenSCs)” NCT01483248 ↗ |
| Modality | Cell therapy | “stem cell transplantation” NCT01483248 ↗ |
| Route | Intravenous | “taken i.v.” NCT01483248 ↗ |